Key Takeaways ImmunityBio shares rose 11% after China approved Anktiva combo for bladder cancer treatment.Approval in China covers BCG-unresponsive NMIBC with CIS with or without papillary tumors.Anktiva plus BCG combo showed 71% complete response rate in the QUILT-3.032 study.Shares of ImmunityBio (IBRX) were up 11% on Monday after the company announced that Macau’s regulatory body has approved its lead drug, Anktiva, for treating certain patients with a type of bladder cancer.The regulatory body has appro ...